Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
about
Phenotype standardization for statin-induced myotoxicityNeuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?Alirocumab for the treatment of hypercholesterolaemia.Development and validation of algorithms for the detection of statin myopathy signals from electronic medical records.Statin-associated myopathy. Assessment of frequency based on data of all statutory health insurance funds in Germany.
P2860
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Risk of hospitalized rhabdomyo ...... a real-world clinical setting.
@en
Risk of hospitalized rhabdomyo ...... a real-world clinical setting.
@nl
type
label
Risk of hospitalized rhabdomyo ...... a real-world clinical setting.
@en
Risk of hospitalized rhabdomyo ...... a real-world clinical setting.
@nl
prefLabel
Risk of hospitalized rhabdomyo ...... a real-world clinical setting.
@en
Risk of hospitalized rhabdomyo ...... a real-world clinical setting.
@nl
P2093
P1476
Risk of hospitalized rhabdomyo ...... a real-world clinical setting.
@en
P2093
James M McKenney
Mark J Cziraky
Maxine D Fisher
Michael H Davidson
Siddhesh A Kamat
Vincent J Willey
P304
P356
10.1016/J.JACL.2012.06.006
P407
P577
2012-07-03T00:00:00Z